Drugs / Trivalent Inactivated Influenza Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01047202 Comparator | Dec 2009 → Mar 2010 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent Inactivated Influenza Vaccine | “Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre.” NCT01047202 ↗ |
| Known as | ANFLU | “Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre.” NCT01047202 ↗ |
| Modality | Vaccine | “or a seasonal influenza vaccine” PMID 23134570 ↗ Nov 2012 |
| Route | Intramuscular | “Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm” NCT01047202 ↗ |